NSW Annual Report Describing Adverse Events Following Immunisation, 2011
Deepika Mahajan A D , Su Reid B , Jane Cook C , Kristine Macartney A and Robert I. Menzies AA National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead
B Health Protection NSW
C Office of Medicine Safety Monitoring, Therapeutic Goods Administration
D Corresponding author. Email: DeepikM2@chw.edu.au
NSW Public Health Bulletin 23(10) 187-200 https://doi.org/10.1071/NB12081
Published: 12 December 2012
Abstract
Abstract: Aim: This report summarises Australian passive surveillance data for adverse events following immunisation in NSW for 2011. Methods: Analysis of de-identified information on all adverse events following immunisation reported to the Therapeutic Goods Administration. Results: 449 adverse events following immunisation were reported for vaccines administered in 2011; this is slightly higher than in 2010 (n = 439) and the second highest number since 2003. The most commonly reported reactions were injection site reaction, fever, allergic reaction and malaise. A large number of injection site reactions were reported following administration of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years and over (97.4/100 000 doses) and in children aged less than 7 years following administration of the 13-valent pneumococcal conjugate vaccine (29.4/100 000 doses) and combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines (47.1/100 000 doses). Only 10% of the reported adverse events were categorised as serious. There were two reports of death however both were attributed to causes other than vaccination. Conclusion: The increased number of reports in 2011 is attributable to the high rates of injection site reactions in children associated with the administration of combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines and the 13-valent pneumococcal conjugate vaccine, as well as in adults following receipt of the 23-valent pneumococcal polysaccharide vaccine.
References
[1] Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization. Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. 2012. Available at: http://www.cioms.ch/frame_vaccine_pharmacovigilance.htm (Cited 18 May 2012).[2] Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 2004; 28 324–38.
[3] Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006; 30 319–33.
[4] Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008; 32 371–87.
[5] Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Commun Dis Intell 2005; 29 248–62.
[6] Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell 2007; 31 269–82.
[7] Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 2009; 33 365–81.
[8] Mahajan D, Cook J, Mclntyre P, Macartney K, Menzies R. Annual report: surveillance of adverse events following immunisation in Australia, 2010. Commun Dis Intell 2011; 35 263–80.
[9] Mahajan D, Campbell-Lloyd S, Roomiani I, Menzies R. NSW Annual Adverse Events Following Immunisation Report, 2009. N S W Public Health Bull 2010; 21 224–33.
| NSW Annual Adverse Events Following Immunisation Report, 2009.Crossref | GoogleScholarGoogle Scholar |
[10] Mahajan D, Campbell-Lloyd S, Cook J, Menzies RI. NSW Annual Report Describing Adverse Events Following Immunisation, 2010. N S W Public Health Bull 2011; 22 196–208.
| NSW Annual Report Describing Adverse Events Following Immunisation, 2010.Crossref | GoogleScholarGoogle Scholar |
[11] Australian Government Department of Health and Ageing. Immunise Australia program. Pneumococcal Disease: Recent changes to pneumococcal vaccine for children Program providing a supplementary dose of Prevenar 13®. Available at: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-pneumococcal (Cited 2 May 2012).
[12] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Pneumovax® 23: Recall of vaccine batch N3336. 25 March 2011. Available at: http://www.tga.gov.au/safety/alerts-medicine-pneumovax-110325.htm (Cited 2 May 2012).
[13] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Pneumovax 23 – Recommendation about revaccination. 18 April 2011. Available at: http://www.tga.gov.au/safety/alerts-medicine-pneumovax-110416.htm (Cited 2 May 2012).
[14] Australian Government Department of Health and Ageing. Immunise Australia program. Australian Technical Advisory Group on Immunisation (ATAGI) Statement – Updated recommendations for revaccination of adults with 23-valent pneumococcal polysaccharide vaccine (23vPPV), Pneumovax 23®. December 2011. Available at: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/pneumo23-atagi-statement-cnt.htm (Cited 31 May 2012).
[15] National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing; 2003.
[16] National Health and Medical Research Council. The Australian Immunisation Handbook. 9th ed. Canberra: Australian Government Department of Health and Ageing; 2008.
[17] Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. 2009. Available at: http://www.who-umc.org/ (Cited 1 February 2009).
[18] Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20 109–17.
| The medical dictionary for regulatory activities (MedDRA).Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXltleksQ%3D%3D&md5=fbd2039d4e9b75088a0dc67967510a3dCAS |
[19] Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)–United States, 1991-2001. MMWR Surveill Summ 2003; 52 1–24.
[20] Australian Bureau of Statistics. 31010DO002_201006 Population by Age and Sex, Australian States and Territories, Jun 2010. Australian Bureau of Statistics; 2010. Released at 11:30 am (Canberra time) 21 December 2010.
[21] Centre for Epidemiology and Research. Summary report on adult health from the NSW Population Health Survey, 2009. Sydney: NSW Department of Health; 2010.
[22] Australian Government Department of Health and Ageing. TGA. Seasonal influenza vaccines: safety advisory. 11 March 2011. Available at: http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-110310.htm (Cited 1 June 2012).
[23] Australian Government Department of Health and Ageing. Immunise Australia program. Chief Medical Officer advice: Seasonal influenza vaccination. 7 March 2011. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-cmo (Cited 1 June 2012).
[24] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian Public Assessment Report for Pneumococcal Polysaccharide Conjugate Vaccine (Prevenar 13®). Available at: http://www.tga.gov.au/pdf/auspar/auspar-prevenar13.pdf (Cited 1 June 2012).
[25] Simon LS. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 2002; 61 ii88–9.
[26] Rennels MB. Extensive swelling reactions occuring after booster doses of Diphtheria-tetanus-Acellular Pertussis vaccines. Seminars in Pediatr Infect Dis J 2003; 14 196–8.
[27] Liese JG, Stojanov S, Zink TH, Froeschle J, Klepadlo R, Kronwitter A., et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Pediatr Infect Dis J 2001; 20 981–8.
| Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3Mrmt1Oitw%3D%3D&md5=17e64c48a5e511332858b5dec712b5d3CAS |
[28] NNDSS Annual report writing group Australia's notifiable disease status, 2009: Annual report of the National Notifiable Disease Surveillance System. Commun Dis Intell 2011; 35 61–131.
[29] Hull B, Dey A, Mahajan D, Menzies RI, McIntyre PB. Immunisation coverage annual report, 2009. Commun Dis Intell 2011; 35 132–48.
